Patents by Inventor Michael Naso

Michael Naso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-tissue factor antibodies and compositions
    Patent number: 9708410
    Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: July 18, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: G. Mark Anderson, Bernard Scallon, Michael Naso, Ann Cai, Cam Holland
  • ST2L Antagonists and Methods of Use
    Publication number: 20170066831
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: November 12, 2015
    Publication date: March 9, 2017
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
    Patent number: 9587024
    Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?v?3 integrin, as well as methods of use in the treatment of diseases and disorders.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: March 7, 2017
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David Clemmons, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon William Keen
  • ANTI-TISSUE FACTOR ANTIBODIES AND COMPOSITIONS
    Publication number: 20160194405
    Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.
    Type: Application
    Filed: January 11, 2016
    Publication date: July 7, 2016
    Inventors: G. Mark Anderson, Bernard Scallon, Michael Naso, Ann Cai, Cam Holland
  • ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
    Patent number: 9212227
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 15, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • Methods and Vectors for Generating Asialylated Immunoglobulins
    Publication number: 20150291946
    Abstract: The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the Fc?RI, Fc?RIIA, and Fc?RIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity.
    Type: Application
    Filed: February 10, 2015
    Publication date: October 15, 2015
    Inventors: Michael Naso, T. Shantha Raju, Bernard Scallon
  • Monoclonal Antibodies for Enhancing or Inhibiting Insulin-Like Growth Factor I (IGF-1)
    Publication number: 20150259422
    Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?v?3 integrin, as well as methods of use in the treatment of diseases and disorders.
    Type: Application
    Filed: June 2, 2015
    Publication date: September 17, 2015
    Inventors: David CLEMMONS, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon William Keen
  • ST2L antibody antagonists
    Patent number: 9090694
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: July 28, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
    Patent number: 9073996
    Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?V?3 integrin, as well as methods of use in the treatment of diseases and disorders.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: July 7, 2015
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David Clemmons, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon William Keen
  • CCL17
    Patent number: 9012602
    Abstract: Isolated polynucleotides encoding Macaca fascicularis CCL17 (CynoCCL17), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: April 21, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Michael Naso, Mary Ryan, Sandra Santulli-Marotto, Bethany Swencki-Underwood
  • Methods and vectors for generating asialylated immunoglobulins
    Patent number: 8975040
    Abstract: The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the Fc?RI, Fc?RIIA, and Fc?RIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: March 10, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Michael Naso, T. Shantha Raju, Bernard Scallon
  • ANTI-TISSUE FACTOR ANTIBODIES AND COMPOSITIONS
    Publication number: 20140079628
    Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Inventors: G. Mark Anderson, Bernard Scallon, Michael Naso, Ann Cai, Cam Ngo
  • MONOCLONAL ANTIBODIES FOR ENHANCING OR INHIBITING INSULIN-LIKE GROWTH FACTOR 1 (IGF-1)
    Publication number: 20140072568
    Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?V?3 integrin, as well as methods of use in the treatment of diseases and disorders.
    Type: Application
    Filed: August 30, 2013
    Publication date: March 13, 2014
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: David Clemmons, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon William Keen
  • Methods and Vectors for Generating Asialylated Immunoglobulins
    Publication number: 20140057319
    Abstract: The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the Fc?RI, Fc?RIIA, and Fc?RIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity.
    Type: Application
    Filed: August 23, 2013
    Publication date: February 27, 2014
    Inventors: Michael Naso, T.Shantha Raju, Bernard Scallon
  • ST2L Antagonists and Methods of Use
    Publication number: 20130336980
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: March 13, 2013
    Publication date: December 19, 2013
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiu Wu
  • ST2L Antagonists and Methods of Use
    Publication number: 20130287777
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 31, 2013
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiu Wu
  • Methods and vectors for generating asialylated immunoglobulins
    Patent number: 8540992
    Abstract: The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the Fc?RI, Fc?RIIA, and Fc?RIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity.
    Type: Grant
    Filed: December 26, 2007
    Date of Patent: September 24, 2013
    Inventors: Michael Naso, T. Shantha Raju, Bernard Scallon
  • IL-17A antibodies
    Patent number: 8519107
    Abstract: Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: August 27, 2013
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Daniela Della Ducata, Merle Elloso, Jinquan Luo, Thomas Malia, Michael Naso, Galina Obmolova, Robert Rauchenberger, Mark Rutz, Raymond Sweet, Susann Taudte, Bingyuan Wu, Sheng-Jiun Wu
  • Baboon homolog of human CD147
    Patent number: 8338171
    Abstract: Polynucleotide sequences encoding a baboon homolog of human CD147 and polypeptides obtainable form the polynucleotides and uses are disclosed.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: December 25, 2012
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Bethany Swencki-Underwood, Michael Naso
  • Monkey homolog of human oncostatin M and methods of use thereof
    Patent number: 8309688
    Abstract: Cytokine oncostatin M nucleic acids from Cynomolgus monkey are useful for expression of oncostatin M proteins that are functional homologs of human oncostatin M. The nucleic acids and proteins produced therefrom are useful in screening and safety testing of oncostatin M, the generation and testing of oncostatin M modulators and related activities.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: November 13, 2012
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Adam Cotty, Michael Naso